SPOTLIGHT: Worst Pharma Stocks of 2007

When we set out last week to identify the best-performing pharma stocks of 2007, we could resist scrolling to the bottom of the spreadsheet to see what happened on the opposite end of the spectrum. And we figured you'd be equally curious. So here for your perusing pleasure are the 15 companies whose shares lost the most value last year. Special Report

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.